1.	E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-701, 2011-000752-41, NCT01271504
2.	E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-702, 2011-000773-31, NCT01332266
3.	E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) Phase: Phase II, Phase I Type: Treatment Status: Active Age: not specified Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-G000-901, NCT01433991
4.	A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-E044-101, NCT00869895
5.	A Phase I Study of E7050 in Subjects With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-J081-110, NCT01428141